Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy
Progress in the use of traditional chemotherapy and radiation-based strategies for the treatment of pediatric malignancies has plateaued in the past decade, particularly for patients with relapsing or therapy refractory disease. As a result, cellular and humoral immunotherapy approaches have been in...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2015-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2015/675269 |
id |
doaj-ec3b0465df3f45f797a477e891ce03a0 |
---|---|
record_format |
Article |
spelling |
doaj-ec3b0465df3f45f797a477e891ce03a02020-11-24T22:23:17ZengHindawi LimitedJournal of Immunology Research2314-88612314-71562015-01-01201510.1155/2015/675269675269Cellular and Antibody Based Approaches for Pediatric Cancer ImmunotherapyMichael A. Huang0Deepa K. Krishnadas1Kenneth G. Lucas2Department of Pediatrics, Hematology/Oncology, University of Louisville, Louisville, KY 40202, USADepartment of Pediatrics, Hematology/Oncology, University of Louisville, Louisville, KY 40202, USADepartment of Pediatrics, Hematology/Oncology, University of Louisville, Louisville, KY 40202, USAProgress in the use of traditional chemotherapy and radiation-based strategies for the treatment of pediatric malignancies has plateaued in the past decade, particularly for patients with relapsing or therapy refractory disease. As a result, cellular and humoral immunotherapy approaches have been investigated for several childhood cancers. Several monoclonal antibodies are now FDA approved and commercially available, some of which are currently considered standard of practice. There are also several new cellular immunotherapy approaches under investigation, including chimeric antigen receptor (CAR) modified T cells, cancer vaccines and adjuvants, and natural killer (NK) cell therapies. In this review, we will discuss previous studies on pediatric cancer immunotherapy and new approaches that are currently being investigated in clinical trials.http://dx.doi.org/10.1155/2015/675269 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Michael A. Huang Deepa K. Krishnadas Kenneth G. Lucas |
spellingShingle |
Michael A. Huang Deepa K. Krishnadas Kenneth G. Lucas Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy Journal of Immunology Research |
author_facet |
Michael A. Huang Deepa K. Krishnadas Kenneth G. Lucas |
author_sort |
Michael A. Huang |
title |
Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy |
title_short |
Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy |
title_full |
Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy |
title_fullStr |
Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy |
title_full_unstemmed |
Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy |
title_sort |
cellular and antibody based approaches for pediatric cancer immunotherapy |
publisher |
Hindawi Limited |
series |
Journal of Immunology Research |
issn |
2314-8861 2314-7156 |
publishDate |
2015-01-01 |
description |
Progress in the use of traditional chemotherapy and radiation-based strategies for the treatment of pediatric malignancies has plateaued in the past decade, particularly for patients with relapsing or therapy refractory disease. As a result, cellular and humoral immunotherapy approaches have been investigated for several childhood cancers. Several monoclonal antibodies are now FDA approved and commercially available, some of which are currently considered standard of practice. There are also several new cellular immunotherapy approaches under investigation, including chimeric antigen receptor (CAR) modified T cells, cancer vaccines and adjuvants, and natural killer (NK) cell therapies. In this review, we will discuss previous studies on pediatric cancer immunotherapy and new approaches that are currently being investigated in clinical trials. |
url |
http://dx.doi.org/10.1155/2015/675269 |
work_keys_str_mv |
AT michaelahuang cellularandantibodybasedapproachesforpediatriccancerimmunotherapy AT deepakkrishnadas cellularandantibodybasedapproachesforpediatriccancerimmunotherapy AT kennethglucas cellularandantibodybasedapproachesforpediatriccancerimmunotherapy |
_version_ |
1725765046164783104 |